Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 11/20 | 0.42 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | PSMB1 | P20618 | 3/20 | 0.35 |
| ▸ | PSMB2 | P49721 | 3/20 | 0.35 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.34 |
| ▸ | TNF | P01375 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6168245 | 0.89 | MMP13 (0.45) | MMP13SLC22A8PSMB1PSMB2PSMB5 | |
| SCHEMBL6167249 | 0.81 | MMP13 (0.56) | MMP13SLC22A8 | |
| SCHEMBL6168302 | 0.81 | MMP13 (0.44) | MMP13SLC22A8PSMB1PSMB2PSMB5 | |
| SCHEMBL6176565 | 0.80 | KDM4E (0.49) | MMP13SLC22A8TNFKDM4E | |
| SCHEMBL6169541 | 0.80 | MMP13 (0.46) | MMP13SLC22A8PSMB1PSMB2PSMB5 | |
| SCHEMBL6702274 | 0.79 | MMP13 (0.43) | MMP13SLC22A8PSMB1PSMB2PSMB5 | |
| SCHEMBL6704440 | 0.79 | TNF (0.59) | MMP13SLC22A8TNFKDM4E | |
| SCHEMBL6171522 | 0.79 | MMP13 (0.46) | MMP13SLC22A8PSMB1PSMB2KDM4E | |
| SCHEMBL6180019 | 0.78 | MMP13 (0.51) | MMP13SLC22A8PSMB1PSMB2PSMB5 | |
| SCHEMBL6175431 | 0.77 | TNF (0.64) | MMP13TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040044000-A1 | Isoquinoline derivatives as matrix metalloproteinase inhibitors | BUNKER AMY MAE (US) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044000-A1 | Isoquinoline derivatives as matrix metalloproteinase inhibitors | MMP1, MMP13, MMP9 | MMP13 2/4885SLC22A8 1532/4885PKM 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.